Related Experiment Video

Updated: Oct 5, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K

Pomalidomide-based therapy for extramedullary multiple myeloma

Yating Li1, Jiamei Ji1, Hua Lu1

  • 1The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.

Hematology (Amsterdam, Netherlands)
|January 24, 2022
PubMed
Abstract

Insights

Pomalidomide-based therapy shows promise for treating extramedullary disease (EMD) in multiple myeloma (MM) patients. This approach achieved significant response rates and improved survival, offering a new option for difficult-to-treat EMD.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Extramedullary disease (EMD) in multiple myeloma (MM) presents a significant challenge, often associated with poor prognosis.
  • Effective treatment strategies for EMD, particularly with novel agents, remain limited.
  • Pomalidomide is a novel immunomodulatory drug with potential in MM treatment.

Purpose of the Study:

  • To evaluate the efficacy of pomalidomide-based therapy in patients with multiple myeloma and extramedullary disease.
  • To assess response rates and survival outcomes in this patient population.

Main Methods:

  • Retrospective analysis of six patients with EMD treated with pomalidomide-based therapy.
  • Evaluation of serological and extramedullary response rates.
  • Assessment of progression-free survival (PFS) and overall survival (OS).

Main Results:

  • An overall response rate (ORR) of 83% was observed for extramedullary disease, with 50% complete response (CR) and 33% partial response (PR).
  • Serological response included 16% CR and 67% PR.
  • Median PFS was 5 months and median OS was 8 months from EMD diagnosis.

Conclusions:

  • Pomalidomide-based therapy demonstrated efficacy in previously treated patients with EMD.
  • These findings suggest pomalidomide as a viable treatment option for refractory EMD in MM.
Keywords:
Pomalidomideefficacyextramedullary diseasemultiple myeloma

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.6K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282